论文部分内容阅读
乙型肝炎发病广泛,影响着3.5亿人口(占世界人口的5％)。在受感染的儿童体内,病毒的复制尤其活跃,因此在患儿血清中可出现HBeAg,且HBV DNA呈高水平。成人慢性乙型肝炎的治疗可选择包括核苷类似物拉米夫定及细胞因子α干扰素。然而,对于儿童来说α干扰素治疗给药麻烦而不易接受,且有不可预知的副作用。由于拉米夫定对成人的治愈成功率与干扰素相似,因此作者在本研究中对拉米夫定治疗儿童慢性乙型肝炎的安全性及有效性方面进行了评估。
Hepatitis B is widespread and affects 350 million people (5% of the world’s population). In infected children, viral replication is particularly active, so HBeAg can be present in the serum of children with high levels of HBV DNA. Adult chronic hepatitis B treatment options include the nucleoside analogues lamivudine and cytokine interferon. However, alpha interferon therapy is cumbersome and unacceptable to children with unpredictable side effects. Since lamivudine has a similar success rate of interferon treatment in adults, the authors evaluated the safety and efficacy of lamivudine in the treatment of childhood chronic hepatitis B in this study.